On September 30, 2022 PACT Pharma, Inc., a privately held biopharmaceutical company developing transformational personalized neoantigen-specific and off-the-shelf T cell receptor (TCR) T cell therapies for the eradication of solid tumors, reported that it has entered into an agreement to sell select assets to AmplifyBio, a contract research organization focused on accelerating innovation across pharmaceutical modalities (Press release, PACT Pharma, SEP 30, 2022, View Source [SID1234621622]). Under terms of the agreement, AmplifyBio will acquire advanced characterization platforms and bioinformatics capabilities from PACT to enhance the company’s cell and gene therapy characterization capabilities. Additionally, AmplifyBio will acquire PACT’s South San Francisco facility along with a number of technical operations and product characterization domain experts.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Importantly, this agreement allows PACT to retain its proprietary research and development capabilities and improve its overall financial position. This will allow the company to continue its mission of developing neoantigen-targeted TCR T cell therapies for the treatment of solid tumors. The company is actively advancing its novel development programs and expects to file an Investigational New Drug application for a novel neoantigen-targeted TCR T cell therapy in 2023.
"This is an important strategic transaction for PACT and our long-term goal of developing transformative personalized TCR T cell therapies for the treatment of patients with solid tumors. The sale of these select assets to AmplifyBio provides the company with meaningful capital while reducing our operating expenses," said Scott Garland, chief executive officer of PACT Pharma. "At the same time, this agreement has the potential to help advance the field of adoptive cell therapies by allowing AmplifyBio to offer the innovative product characterization platforms developed by the PACT team to a broad range of its clients. By leveraging this platform, these clients will have advanced tools to better understand the critical immunological parameters for successful adoptive cell therapies."